Describing the firm's focus as "Neuroprotective Innovation for Human Health", management of Neurexis note that millions of persoens annually experience stroke /cardiac arrest. Observing that - while life-saving - restoring blood flow to the brain is not sufficient to reverse/affect the substantial impact on quality of life and healthcare costs associated with the resulting neuronal death and cognitive impairment. Loss of blood flow to the brain can be the result of various factors: Stroke, cardiac arrest/global cerebral ischemia, sickle cell anemia, congenital heart defects, high-risk vascular surgery, pre-existing coronary disease, etc. Management further note that - paradoxically - re-establishment of circulation triggers a cascade of proinflammatory events resulting in extensive nerve cell death, and significant cognitive and functional impairment. With no drugs available to address this deficiancy Neurexis management is positioning Neurexis to address that deficiency. No drugs are available, leaving a tremendous market opportunity for a product. The firm is developing tatCN19o, an optimized peptide with demonstrated efficacy and safety in small and large animal models of global cerebral ischemia.
